Development of a CCR2 targeted 18F-labeled radiotracer for atherosclerosis imaging with PET
Copyright © 2024 Elsevier Inc. All rights reserved..
Atherosclerosis is a chronic inflammatory disease and the leading cause of morbidity and mortality worldwide. CC motif chemokine ligand 2 and its corresponding cognate receptor 2 (CCL2/CCR2) signaling has been implicated in regulating monocyte recruitment and macrophage polarization during inflammatory responses that plays a pivotal role in atherosclerosis initiation and progression. In this study, we report the design and synthesis of a novel 18F radiolabeled small molecule radiotracer for CCR2-targeted positron emission tomography (PET) imaging in atherosclerosis. The binding affinity of this radiotracer to CCR2 was evaluated via in vitro binding assay using CCR2+ membrane and cells. Ex vivo biodistribution was carried out in wild type mice to assess radiotracer pharmacokinetics. CCR2 targeted PET imaging of plaques was performed in two murine atherosclerotic models. The sensitive detection of atherosclerotic lesions highlighted the potential of this radiotracer for CCR2 targeted PET and warranted further optimization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130-131 |
|---|---|
| Enthalten in: |
Nuclear medicine and biology - 130-131(2024) vom: 29. März, Seite 108893 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Xiaohui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
(18)F radiolabeling |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nucmedbio.2024.108893 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369128192 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369128192 | ||
| 003 | DE-627 | ||
| 005 | 20240329000631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nucmedbio.2024.108893 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM369128192 | ||
| 035 | |a (NLM)38422918 | ||
| 035 | |a (PII)S0969-8051(24)00019-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Xiaohui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a CCR2 targeted 18F-labeled radiotracer for atherosclerosis imaging with PET |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a Atherosclerosis is a chronic inflammatory disease and the leading cause of morbidity and mortality worldwide. CC motif chemokine ligand 2 and its corresponding cognate receptor 2 (CCL2/CCR2) signaling has been implicated in regulating monocyte recruitment and macrophage polarization during inflammatory responses that plays a pivotal role in atherosclerosis initiation and progression. In this study, we report the design and synthesis of a novel 18F radiolabeled small molecule radiotracer for CCR2-targeted positron emission tomography (PET) imaging in atherosclerosis. The binding affinity of this radiotracer to CCR2 was evaluated via in vitro binding assay using CCR2+ membrane and cells. Ex vivo biodistribution was carried out in wild type mice to assess radiotracer pharmacokinetics. CCR2 targeted PET imaging of plaques was performed in two murine atherosclerotic models. The sensitive detection of atherosclerotic lesions highlighted the potential of this radiotracer for CCR2 targeted PET and warranted further optimization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (18)F radiolabeling | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a CCR2 | |
| 650 | 4 | |a Macrophages | |
| 650 | 4 | |a PET/CT | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 700 | 1 | |a Qiu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Sultan, Debbie H |e verfasserin |4 aut | |
| 700 | 1 | |a Luehmann, Hannah P |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yanbo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiuli |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, Gyu Seong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Alexandria |e verfasserin |4 aut | |
| 700 | 1 | |a Lahad, Divangana |e verfasserin |4 aut | |
| 700 | 1 | |a Rho, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Zhude |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yongjian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nuclear medicine and biology |d 1996 |g 130-131(2024) vom: 29. März, Seite 108893 |w (DE-627)NLM075154803 |x 1872-9614 |7 nnns |
| 773 | 1 | 8 | |g volume:130-131 |g year:2024 |g day:29 |g month:03 |g pages:108893 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nucmedbio.2024.108893 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130-131 |j 2024 |b 29 |c 03 |h 108893 | ||